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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYIn various vertebrate species, the dorsal aorta (Ao) is the site of specification of adult hematopoietic stem cells (HSCs). It has been observed
that the upregulation of essential hematopoietic transcription factors and the formation of specific intra-aortic hematopoietic cell
clusters occur predominantly in the ventral domain of the Ao (AoV). In the mouse, the first HSCs emerge in the AoV. Here, we demon-
strate that in the human embryo the first definitive HSCs also emerge asymmetrically and are localized to the AoV, which thus identifies
a functional niche for developing human HSCs. Using magnetic cell separation and xenotransplantations, we show that the first
human HSCs are CD34+VE-cadherin+CD45+C-KIT+THY-1+Endoglin+RUNX1+CD38/loCD45RA. This population harbors practically
all committed hematopoietic progenitors and is underrepresented in the dorsal domain of the Ao (AoD) and urogenital ridges (UGRs).
The present study provides a foundation for analysis of molecular mechanisms underpinning embryonic specification of human HSCs.INTRODUCTION
Hematopoietic stem cells (HSCs) emerge early during
embryogenesis and maintain multilineage hematopoiesis
throughout the entire lifespan of the organism through
continuous self-renewal and differentiation (Dzierzak and
Speck, 2008;Medvinsky et al., 2011). Although early devel-
opment of mouse HSCs has been extensively investigated,
early human HSC development is poorly understood. A
better understanding of this process could be of practical
importance. Bone marrow and umbilical cord blood-
derived HSC transplantation is performed for a number
of therapeutic indications in the clinic, but the availability
of suitable donors is inadequate. Many research groups
are investigating the possibility of generating HSCs
under controlled conditions in the laboratory. Embryonic
and induced pluripotent stem cells can differentiate
in vitro into the majority of cell types, including various
hematopoietic cells, and could be an ideal source of
customized HSCs for clinical applications (Kaufman,
2009). However, the generation of true transplantable
HSCs remains a significant challenge. A better understand-
ing of the embryonic development of human HSCs may
be instrumental for developing novel protocols for their
generation in vitro.
Due to the poor availability of human embryonic tissues
and the limitations of xenotransplantationmodels, studies
on early human hematopoietic development were largely
based on immunohistological and in vitro techniques,
which did not encompass HSCs (Huyhn et al., 1995; Ober-
lin et al., 2002; Tavian et al., 2001). The development ofStemseverely immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz
(NSG) recipient mice that are highly receptive for human
cells has enhanced the capacity of researchers to study
human HSCs. We recently described the spatiotemporal
distribution of definitive HSCs in the early human embryo
and determined that they first emerge in the aorta-gonad-
mesonephros (AGM) region, specifically in the dorsal
aorta (Ao) (Ivanovs et al., 2011). HSCs appear later in the
yolk sac, liver, and placenta. Notably, we showed that
human AGM region HSCs possess very high self-renewal
potential, with each HSC producing more than 300
daughter HSCs in primary NSG recipient mice. This is
reflected by the high level of human hematopoietic repo-
pulation (reaching up to 95% of total peripheral blood
leukocytes) seen in NSG mice transplanted with a single
HSC from the human AGM region. To achieve the same
effect with human umbilical cord blood HSCs, consider-
ably higher numbers of HSCs need to be transplanted
(Liu et al., 2010). Similar observations showing that
developmentally younger fetal liver HSCs possess higher
self-renewal capacity than their adult bone marrow coun-
terparts have been made in the mouse model (Copley
et al., 2013; Pawliuk et al., 1996).
During embryogenesis, various vertebrate species harbor
hematopoietic cell clusters attached to the ventral wall of
the Ao (Emmel, 1916; Jaffredo et al., 1998; Minot, 1912;
Yokomizo and Dzierzak, 2010). Since the early HSCs and
hematopoietic progenitors share common markers with
endothelial cells (Taoudi et al., 2005), it is widely thought
that hematopoietic cells are formed through budding
from the ventral aortic endothelium and possibly resideCell Reports j Vol. 2 j 449–456 j April 8, 2014 j ª2014 The Authors 449
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Chen et al., 2009; Kissa and Herbomel, 2010). In line
with this, the expression of a number of key transcription
factors and secretedmolecules known to be involved in he-
matopoietic specification during embryogenesis, such as
RUNX1, SCL, C-MYB, GATA2, GATA3, BMP4, and LMO2,
is biased toward the ventral domain of the Ao (AoV) (Ber-
trand et al., 2005; Durand et al., 2007; Elefanty et al.,
1999; Manaia et al., 2000; Marshall et al., 1999, 2000;
North et al., 1999;Wilkinson et al., 2009). The sympathetic
nervous system cells underlying the AoV contribute to
the generation of definitive HSCs through secretion of
catecholamines (Fitch et al., 2012). Furthermore, long-
term repopulation studies in the mouse showed that the
AoV, as opposed to the dorsal domain of the Ao (AoD), is
the primary functional niche for the specification of defin-
itive HSCs (Taoudi and Medvinsky, 2007). In vivo imaging
of the zebrafish embryo has provided strong evidence that
zebrafish definitive HSCs/multipotent hematopoietic pro-
genitors emerge through the endothelio-hematopoietic
transition in the AoV (Bertrand et al., 2010; Kissa and
Herbomel, 2010). Although the existence of dorsoventral
polarity during human hematopoietic development has
already been established at the morphological and gene-
expression level (Marshall et al., 1999, 2000; Minot,
1912), the ventral origin of HSCs remains a long-standing
hypothesis.
Identification of the niche and phenotype of the first
definitive HSCs that emerge in the human embryo is of
high importance for elucidating the biology of these cells
and investigating the mechanisms that underlie their
development and high regenerative potential. However,
this analysis is hampered by the limited availability of
human embryonic tissues and the extreme rarity of HSCs
in the human AGM region. Only one or two definitive
HSCs can be identified at any one time in the human
AGM region at the preliver stage of HSC development
(Ivanovs et al., 2011). Assuming conservation of biological
processes between species, we used knowledge obtained in
the mouse model to identify the phenotype and niche of
human HSCs (Medvinsky et al., 2011).
In this study, we demonstrate a strong dorsoventral
polarization of hematopoietic activity in the human Ao,
with the AoV containing significantly more hematopoietic
cells and committed hematopoietic progenitors than the
AoD. Furthermore, we show that the long-term, multiline-
age repopulating activity resides exclusively in the AoV,
which thus represents the functional niche for develop-
ing human HSCs. We show that the CD34+VE-cadherin+
CD45+C-KIT+THY-1+Endoglin+RUNX1+CD38/loCD45RA
phenotype defines the identity of the earliest human HSCs
and provides up to 1,000-fold enrichment for HSCs in
the total AGM region cell population. Our identification450 Stem Cell Reports j Vol. 2 j 449–456 j April 8, 2014 j ª2014 The Authorof the niche and phenotype of the earliest human HSCs
provides a strong foundation for analyzing the molecular
mechanisms that underlie their specification and high
regenerative potential.RESULTS
Asymmetric Distribution of Hematopoietic Cells
and Progenitors within the Human AGM Region
To establish the spatial distribution of hematopoietic
cells within the human AGM region, we performed five
independent experiments with Carnegie stage (CS) 14–17
human embryos. The expression of CD45, a panhemato-
poietic marker, and CD34, a marker of human adult
HSCs and hematopoietic progenitors, was assessed by
flow-cytometry analysis of cells isolated from the AoV,
AoD, and urogenital ridges (UGRs). The AoV and the AoD
included the ventral and the dorsal aortic endothelium,
respectively, and the surrounding mesenchyme. The
UGRs included the mesonephroi and gonadal rudiments
along with the surrounding mesenchyme. All dissections
(Figure S1 available online) were performed as previously
described for the mouse embryo (Taoudi and Medvinsky,
2007). The AoV contained significantly more hemato-
poietic (CD45+) cells than the AoD, but a similar number
compared with the UGRs (Figure 1A). We found that
the AoV contained a distinct population of CD34+VE-
cadherin+CD45+ cells, which was virtually absent in the
AoD and UGRs (Figures 1B and 1D). In five independent
experiments, single-cell suspensions prepared from the
AoV, AoD, and UGRs were plated into methylcellulose me-
dium supplemented with human cytokines. After 14 days,
hematopoietic colonies were scored.Whereas the AoV con-
tained 210 ± 130 colony-forming units in culture (CFU-Cs)
per embryo equivalent (e.e.), the AoD and UGRs contained
only 30 ± 20 and 40 ± 30 CFU-Cs per e.e., respectively
(Figure 1C).The AoV Is the Niche for the Emerging Human
Definitive HSCs
We previously reported that the Ao, but not the UGRs,
possess HSC activity within the human AGM region
(Ivanovs et al., 2011). To determine whether the first hu-
man HSCs emerge in the AoV, we performed ten inde-
pendent experiments in which the Ao of CS 15–17 human
embryos was bisected into the AoV and AoD. Single-cell
suspensions prepared from these tissues were individually
transplanted into sublethally irradiated adult NSG recip-
ient mice. In six out of ten experiments, we detected hu-
man high-level, long-term, multilineage hematopoietic
engraftment derived exclusively from the AoV, but
never from the AoD. The recipients showed progressivelys
Figure 1. Dorsoventral Polarization of
Hematopoietic Activity in the Human
AGM Region
(A–C) AGM regions from five CS 14–17
human embryos were dissected into AoV,
AoD, and UGRs (Figure S1), and single-cell
suspensions were prepared from these
tissues. CD45+ and CD34+CD45+ cell numbers
per e.e. were assessed by flow cytometry.
CFU-C numbers per e.e. were evaluated
using methylcellulose culture. Tissues from
the same embryo are represented by the
same symbol on the plots. Mean values ± SD
are shown.
(D) CD34, VE-cadherin, and CD45 expression
in cells from the AoV, AoD, and UGRs.
VE-cadherin+ cells are overlaid and shown
in red.
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that was readily detectable in the peripheral blood, as pre-
viously described for human AGM region HSCs (Ivanovs
et al., 2011).
Phenotype of Human HSCs in the AGM Region
Based on our studies in the mouse (Rybtsov et al., 2011;
Taoudi et al., 2005, 2008), we were interested in testing
whether human AGM region HSCs express VE-cadherin
and CD45. Flow-cytometry analysis demonstrated that
the human AGM region VE-cadherin+CD45+ cells are
entirely positive for CD34, C-KIT, THY-1, endoglin, and
RUNX1, and negative for CD38 and CD45RA (Figure 2A).
This suggests the presence of HSCs in the VE-cadher-
in+CD45+ cell population. To confirm this, we employed
magnetic cell separation using beads coupled with either
anti-CD45 or anti-VE-cadherin antibodies. Antigen-posi-
tive and -negative cell populations were isolated from
CS 15–17 human AGM regions and individually trans-
planted into sublethally irradiated adult NSG mice. In
two out of three independent experiments performed
with anti-human CD45 magnetic beads, HSC activity
was detected exclusively within the CD45+ cell popula-
tion (Table 1). However, in six independent experiments,Stemnone of the recipients transplanted with the VE-cad-
herin+ or VE-cadherin cell populations were repopulated
(Table 1). Although the anti-VE-cadherin antibody we
used here was successfully employed to purify human
fetal liver-derived HSCs (Oberlin et al., 2010), our data
indicated that the VE-cadherin antibody interferes with
the functional properties of HSCs isolated from the
AGM region. Indeed, we found the same inhibitory effect
in the mouse model (Figure S2). In three independent
experiments, mouse embryonic day 11.5 (E11.5) AGM
region cells were incubated with anti-mouse antibodies
to CD45, VE-cadherin, or both combined, and directly
transplanted into sublethally irradiated adult recipients.
Unlabeled cells were transplanted as a positive control.
Cells that were incubated with the anti-VE-cadherin
antibody alone or in combination with the anti-CD45
antibody showed decreased hematopoietic engraftment
compared with cells that were left untreated or incubated
with the anti-CD45 antibody only. Therefore, VE-cad-
herin is a functionally important surface antigen of
AGM region HSCs, and the failure of human HSCs
to engraft recipient mice upon staining with anti-VE-
cadherin antibody strongly suggests that they express
VE-cadherin.Cell Reports j Vol. 2 j 449–456 j April 8, 2014 j ª2014 The Authors 451
Figure 2. Phenotypic Characterization of
Human AGM Region Cells
(A) CD34, C-KIT, THY-1, endoglin, RUNX1,
CD38, and CD45RA expression in the VE-
cadherin+CD45+ cell population. The dotted
lines indicate fluorescence-minus-one
controls. At least two independent experi-
ments were performed for each antigen.
(B and C) Four cell populations were
sorted from the total AGM region based on
the expression of VE-cadherin and CD45
antigens, and plated in the CFU-C assay.
Four independent experiments were per-
formed. Mean values ± SD are shown. See
also Table S1.
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Development of HSCs in the Human AGM RegionSince VE-cadherin was not suitable for purifying human
AGM region-derived HSCs without affecting their ability
to repopulate NSG recipient mice, we focused on CD34,
which is a principal marker for human adult HSCs (Majeti
et al., 2007). CD34 is also expressed in the endothelium
of the developing human Ao (Oberlin et al., 2002), and
therefore is a reasonable replacement for VE-cadherin. We
isolated CD34+ and CD34 cell populations using mag-
netic beads and individually transplanted them into suble-
thally irradiated adult NSG recipient mice. In two out of
three experiments, HSC activity was detected exclusively
within the CD34+ cell population (Table 1). Thus, HSCs
in the human AGM region are CD34+CD45+. Our experi-452 Stem Cell Reports j Vol. 2 j 449–456 j April 8, 2014 j ª2014 The Authorments strongly suggest that VE-cadherin is also expressed
in these cells, since incubation with the anti-VE-cadherin
antibody suppresses their repopulating activity. Based
on the flow-cytometry analysis data (Figure 2A), the pheno-
type of the first human HSCs can be extended further to
CD34+VE-cadherin+CD45+C-KIT+THY-1+Endoglin+RUNX1+
CD38/loCD45RA.
We then determined the phenotype of committed he-
matopoietic progenitors in the human AGM region. In
four independent experiments, fluorescence-activated cell
sorting (FACS) followed by the CFU-C assay showed that
the vast majority of CFU-Cs reside in the VE-cadher-
in+CD45+ cell population. The average number of CFU-Css
Table 1. Phenotype of Human AGM Region HSCs
Antigen
Cell Population Transplanted
Positive Negative
CD45 2/3 0/3
VE-cadherin 0/6 0/6
CD34 2/3 0/3
Data shown are the number of AGM regions that gave human high-level,
long-term, multilineage hematopoietic engraftment compared with the
total number of AGM regions transplanted. See also Figure S2.
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herin+CD45+, and VE-cadherinCD45+ cell populations
was 0.3 ± 0.5, 3.8 ± 3.0, 89.5 ± 49.9, and 17.8 ± 21.5
CFU-Cs per e.e., respectively (Figures 2B and 2C; Table S1).DISCUSSION
In this study, we focused on the localization and phenotyp-
ing of the first HSCs that emerge in the human embryo.We
found that, as in the E11.5 mouse embryo (Taoudi and
Medvinsky, 2007), HSC development in the human AGM
region is polarized and occurs in the AoV. However, the
asymmetric distribution of hematopoietic activity in the
human AGM region is more pronounced. Although
CD45+ hematopoietic cells and CFU-Cs in the E11.5mouse
Ao are distributed more or less evenly between the AoV
and AoD (Taoudi and Medvinsky, 2007), in humans these
populations reside almost exclusively in the AoV.
Using the long-term repopulation assay, we demon-
strated that the earliest human HSCs are CD34+CD45+.
Expression of CD45 indicates full hematopoietic commit-
ment of these newly emerged HSCs, consistent with find-
ings in the mouse (Taoudi et al., 2005, 2008). Interestingly,
CD34 is also expressed in mouse AGM region HSCs (Sa´n-
chez et al., 1996). In humans, CD34 is a principal marker
for identifying adult HSCs in the bone marrow and umbil-
ical cord blood (Berenson et al., 1991; Majeti et al., 2007).
CD34+CD45+ cells from the human AGM region largely
coexpress VE-cadherin, an important marker for early
HSCs in the mouse embryo (Taoudi et al., 2005). Our data
strongly suggest that the earliest human HSCs are VE-cad-
herin+. VE-cadherin is likely to be a functionally important
surface antigen of AGM region HSCs, since we demon-
strated an attenuation of HSC activity following cell
labeling with the anti-VE-cadherin antibody. Additional
flow-cytometry analysis showed that the CD34+VE-cadher-
in+CD45+ cell population is entirely positive for major
adult HSC markers such as C-KIT, THY-1, and endoglin
(Baum et al., 1992; Chen et al., 2002; Ikuta and Weissman,Stem1992; Majeti et al., 2007; Spangrude et al., 1988), and does
not express negative human adult HSC markers such as
CD38 and CD45RA (Bhatia et al., 1997; Majeti et al.,
2007). In addition, the CD34+VE-cadherin+CD45+ cell
population is almost entirely positive for RUNX1, which
marks developing definitive HSCs in the mouse AGM
region (North et al., 2002). Thus, the population of the first
definitive HSCs that emerge in the human AGM region is
CD34+VE-cadherin+CD45+C-KIT+THY-1+Endoglin+RUNX1+
CD38/loCD45RA. We have found that this cell popu-
lation is virtually absent from the AoD and UGRs, and
contains practically all of the CFU-Cs that reside in the
AGM region. AlthoughHSCs and committed hematopoiet-
ic progenitors are highly enriched in this population, none
of these markers are known to discriminate between HSCs
and CFU-Cs. Similar to the case with the mouse, this
remains an important unresolved issue (Medvinsky et al.,
2011).
Several studies have reported the existence of rare CD34
HSCs upstream of the major population of CD34+ HSCs
in the human hematopoietic hierarchy (Anjos-Afonso
et al., 2013; Bhatia et al., 1998). Interestingly, the first
HSCs found in the human embryo are CD34+ and give
rise exclusively to a CD34+CD38/lo daughter HSC popula-
tion upon xenotransplantation (Ivanovs et al., 2011). Since
the subsequent downregulation of CD34 during further
development cannot be excluded, precise changes in the
phenotype of human HSCs require further study.
In summary, we have demonstrated that the first HSCs
in the human embryo emerge in the ventral niche of
the Ao and are CD34+VE-cadherin+CD45+C-KIT+THY-1+
Endoglin+RUNX1+CD38/loCD45RA. By identifying the
niche and phenotype of the first human definitive HSCs,
this study lays a foundation for identifying and character-
izing themolecularmechanisms that underlie the specifica-
tion and high regenerative potential of the earliest human
HSCs. Such knowledgemay also be essential for developing
protocols to derive human HSCs from embryonic and
induced pluripotent stem cells for use in regenerative
medicine.EXPERIMENTAL PROCEDURES
Source and Processing of Human Embryonic Tissues
Human embryonic tissues were obtained immediately after elec-
tive medical termination of pregnancy. The study was approved
by the Lothian Research Ethics Committee. Each patient gave
informed consent in writing for the use of human embryonic
tissues in research. The developmental stage of human embryos
was determined according to the Carnegie staging system
(Ivanovs et al., 2013; O’Rahilly and Muller, 1987). Isolation and
dissection of the AGM region was performed as described
elsewhere for the mouse embryo (Taoudi and Medvinsky, 2007).Cell Reports j Vol. 2 j 449–456 j April 8, 2014 j ª2014 The Authors 453
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(Ivanovs et al., 2011).Long-Term Repopulation Assays
Experiments with mice were approved by the Animal Welfare
Committee of the University of Edinburgh, Edinburgh, Scotland,
UK. NSG mice were used as recipients for human HSCs. B6.SJL-
Ptprca Pepcb/Boy mice (Ly5.1/Ly5.1) were used as recipients for
HSCs from C57BL/6 mouse embryos (Ly5.2/Ly5.2) and bone
marrow carrier cells from F1 hybrid mice (Ly5.1/Ly5.2). Cell trans-
plantations were performed as described in the Supplemental
Experimental Procedures. The number of transplanted human
embryonic cells was expressed in embryo equivalents (e.e.),
defined as a unit of cells equivalent to the number of cells present
in one tissue.Human CFU-C Assay
CFU-C activity in human embryonic tissues was assessed
by culturing in triplicate single-cell suspensions (0.1–0.05 e.e.
per dish) in MethoCult H4034 Optimum Medium (StemCell
Technologies) for 14 days according to the manufacturer’s
recommendations.Flow-Cytometry Analysis and FACS
Surface antigen staining was performed as described in the Supple-
mental Experimental Procedures. RUNX1 intracellular staining
was performed following surface antigen staining, treatment
with 0.5 mg/ml ethidium monoazide bromide, intense fluorescent
light exposure, and fixation with 2% paraformaldehyde. Intracel-
lular antibody staining and washes were performed in ice-cold
Ca2+ and Mg2+-free PBS supplemented with 2% heat-inactivated
fetal bovine serum and 0.4% Triton X-100 (Sigma-Aldrich).Magnetic Cell Separation
Cell populations of interest were purified using MACS technology
(Miltenyi Biotec). CD45+ and CD34+ cells were enriched using
human CD45 and CD34 MicroBeads. VE-cadherin+ cells were iso-
lated using anti-PE MicroBeads following cell labeling with mouse
anti-human VE-cadherin-PE monoclonal antibody (clone TEA 1/
31; Beckman Coulter). Magnetic cell separation was performed
manually using a QuadroMACS separator and LS columns. Cell
labeling, washes, and isolation were performed in accordance
with the manufacturer’s recommendations.Statistical Analysis
Data are presented as mean ± SD. Comparison between groups
was performed using the paired-samples t test or the Wilcoxon
signed-ranks test. Statistical significance was attributed to pro-
bability value p < 0.05. The above statistical procedures were
performed using SPSS 15.0 software (SPSS).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and one table and can be found with this
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